Search Our Website:

Will Garvin, shareholder in the firm's FDA & Biotechnology section, comments about abuse-resistant opioids, the FDA's position and the expansion of opioid-related litigation in Politico Pro's article "Abuse-Resistant Opioids Fail to Make Gains Amid Crisis." (subscription required)

"They [FDA] would love to approve things that help with abuse-deterrent properties, because from their point of view they want to be seen as doing something," said Will Garvin, a health care attorney who advises clients on drug approvals and regulation.

"There's liability that seems to keep expanding in the opioid space," Garvin said, noting that even if an opioid gets approved with an abuse-deterrent label, it is not protected from liability down the line.